{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:36Z","timestamp":1787962296390,"version":"build-2784847793"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the safety and efficacy of golimumab (GOL), a human antitumor necrosis factor antibody, in patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy through 5 years in the GO-FORWARD trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients with active RA despite MTX therapy were randomly assigned to receive placebo + MTX (Group 1), GOL 100 mg + placebo (Group 2), GOL 50 mg + MTX (Group 3), or GOL 100 mg + MTX (Group 4). Patients in groups 1, 2, and 3 with inadequate response could enter early escape at Week 16 to GOL 50 mg + MTX or GOL 100 mg + MTX, and all remaining Group 1 patients crossed over to GOL 50 mg + MTX at Week 24. The blind was maintained through the 52-week database lock, after which treatment adjustments were permitted. Adverse events (AE) were monitored through Week 268. Efficacy was evaluated using the American College of Rheumatology (ACR) 20\/50\/70 responses and a 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP). Response rates at Week 256 were analyzed by an intent-to-treat analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 444 patients were randomized, and 313 received GOL through Week 252; 301 patients completed the safety followup through Week 268. Infections were the most common type of AE; 172 patients (39.6%) had \u2265 1 serious AE. No unexpected safety signals were observed. At Week 256, ACR20\/50\/70 responses were achieved by 63.1%, 40.8%, and 24.1%, respectively, of all randomized patients. About 78% of all patients achieved a good or moderate DAS28-CRP response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Improvements in the signs and symptoms of RA were maintained through 5 years. AE through 5 years were consistent with earlier reports of the GO-FORWARD trial; no apparent increased risk was observed over time.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.150712","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T02:39:53Z","timestamp":1450233593000},"page":"298-306","source":"Crossref","is-referenced-by-count":45,"title":["Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial"],"prefix":"10.3899","volume":"43","author":[{"given":"Edward C.","family":"Keystone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Gathany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn H.","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,12,15]]},"reference":[{"key":"2018112909351958000_43.2.298.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"2018112909351958000_43.2.298.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116319"},{"key":"2018112909351958000_43.2.298.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120584"},{"key":"2018112909351958000_43.2.298.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111195"},{"key":"2018112909351958000_43.2.298.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30263"},{"key":"2018112909351958000_43.2.298.6","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298188"},{"key":"2018112909351958000_43.2.298.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2018112909351958000_43.2.298.8","doi-asserted-by":"crossref","unstructured":"van Riel PL van Gestel AM Scott DL . EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen aan den Rijn: Van Zuiden Communications BV; 2000.","DOI":"10.1136\/ard.59.suppl_1.i28"},{"key":"2018112909351958000_43.2.298.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"2018112909351958000_43.2.298.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"issue":"Suppl 1","key":"2018112909351958000_43.2.298.11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"2018112909351958000_43.2.298.12","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2018112909351958000_43.2.298.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350105"},{"key":"2018112909351958000_43.2.298.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.146043"},{"key":"2018112909351958000_43.2.298.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.03.003"},{"key":"2018112909351958000_43.2.298.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100752"},{"key":"2018112909351958000_43.2.298.17","first-page":"1232","article-title":"Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909351958000_43.2.298.18","first-page":"1238","article-title":"Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909351958000_43.2.298.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100208"},{"key":"2018112909351958000_43.2.298.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"2018112909351958000_43.2.298.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.008"},{"key":"2018112909351958000_43.2.298.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"2018112909351958000_43.2.298.23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"2018112909351958000_43.2.298.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"2018112909351958000_43.2.298.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.24941"},{"key":"2018112909351958000_43.2.298.26","unstructured":"Emery P Fleischmann RM Strusberg I Durez P Nash P Amante E Efficacy and safety of subcutaneous golimumab in methotrexate-na\u00efve patients with rheumatoid arthritis: 5-year results of the GO-BEFORE trial. Arthritis Care Res 2015 Oct 16 (E-pub ahead of print)."},{"key":"2018112909351958000_43.2.298.27","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0516-6"},{"key":"2018112909351958000_43.2.298.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"2018112909351958000_43.2.298.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.150712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T20:10:54Z","timestamp":1748722254000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.150712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,15]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.3899\/jrheum.150712"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.150712","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,15]]}}}